Team:Evry/Economy

From 2013.igem.org

(Difference between revisions)
m
 
(13 intermediate revisions not shown)
Line 7: Line 7:
<h1>Economy</h1>
<h1>Economy</h1>
-
<p>This section presents an evaluation of the costs (for the patient or the community) of the treatment, and its possible profitability. All the data used for this evaluation are presented below.</p>
+
<p>This section presents an evaluation of the costs for the patient or the community of the treatment, and its possible profitability. All the data used for this evaluation are presented below.</p>
<h2>Treatment costs</h2>
<h2>Treatment costs</h2>
-
<p>Anticipated market price of 1 capsule of Iron-Coli: 10 cent.</p>
+
<p>We first want to know how much will cost our capsule. We estimate that the anticipated <b>market price of 1 capsule of Iron-Coli 10 cent</b>. The relatively low market price of Iron-Coli capsule is due to the fact that it is easy to produce capsules with only one strand of bacteria.
-
<p><b>Bacterial treatment price per patient and per year: 110 euro.</b></p>
+
Further more the market price of current probiotic capsules is between 6 and 35 cent.<a href="#Ref"><sup><small>1,2,3</sup></small></a>
-
<p>Average cost of bloodletting treatment per patient and per year in France: 300 euro.</p>
+
Moreover the patients will have to take 3 capsules each day. So our <b>bacterial treatment price per patient and per year</b> will cost: 0.10 x 3 x 365 = <b>110 euros</b> (~151 $ on the 28/10/2013).</p><br/>
-
<p>Money saved per patient and per year: <b>40 euro</b>.</br>
+
 
-
This does not take into account the costs of a missing half-day's work, or the costs and time of transport, etc. Thus, the collective benefit could be even higher.</p>
+
 
 +
<p>In France, according to Dr. Françoise Courtois (General Secretary of European Federation of Associations of Patients with Haemochromatosis), bloodletting is charged around 40 euros, but costs in reality around 60 euro. The French public welfare system takes charge of all the costs. If a bacterial treatment enables to save money, it will be a collective benefit. According to the presidents of patients' associations, the average number of bloodlettings per patient and per year is 5. The average cost of <b>bloodletting treatment per patient and per year in France</b> is around <b>300 euros</b> (~413 $).</p><br/>
 +
 
 +
<p>We established with our flush model that our treatment will decrease by two the iron absorption and thus by two the number of bloodleting for a patient. So the <b>money saved per patient and per year</b> is (300/2)-110=<b>40 euros</b> (~55 $).</br>
 +
This does not take into account the costs of a missing half-day's work, or the costs and time of transport, etc. Thus, the <b>collective benefit could be even higher</b> !</p>
<br/>
<br/>
<h2>Treatment profitability</h2>
<h2>Treatment profitability</h2>
-
<h3>France</h3>
+
<p> We estimated the cost of the lab' made capsule prototype around <b>3 cents</b>. According to the presidents of patients' associations, there are around <b>100 000 patients in France</b>, and <b>750 000 in Europe</b>.
-
<p>Annual production costs: 3,3 millions euro.</p>
+
Thus we could establish the profitability of our treatment in both France and Europe.</p>
-
<p>Annual income: 7,5 millions euro.</p>
+
-
<p><b>Annual profits: 4,2 millions euro.</b></p>
+
-
<h3>Europe</h3>
+
<table cellpadding="10" cellspacing="0" align='center' border="1">
-
<p>Annual production costs: 25 millions euro.</p>
+
<thead>
-
<p>Annual income: 82 millions euro.</p>
+
  <tr>
-
<p><b>Annual profits: 57 millions euro.</b></p>
+
  <th align="center">
-
<br/>
+
   
-
<br/>
+
  </th>
 +
  <th align="center">
 +
    France
 +
  </th>
 +
  <th align="center">
 +
    Europe
 +
  </th>
 +
  </tr>
 +
</thead>
 +
 
 +
<tbody>
 +
  <tr>
 +
  <td align="center">
 +
    Annual production costs
 +
  </td>
 +
  <td align="center">
 +
    100 000 x 0,03 x 3 x 365
 +
    <br/><b>~3,3 millions euros</b></br>
 +
(~4,5 millions $)
 +
  </td>
 +
 
 +
  <td align="center">
 +
    750 000 x 0,03 x 3 x 365
 +
    <br/><b>~25 millions euros</b><br/>
 +
(~34,5 millions $)
 +
  </td>
 +
  </tr>
 +
  <tr>
 +
  <td align="center">
 +
    Annual income
 +
  </td>
 +
  <td align="center">
 +
    100 000 x 0,1 x 3 x 365
 +
    <br/><b>~11 millions euros</b><br/>
 +
(~15 millions $)
 +
 
 +
  </td>
 +
  <td align="center">
 +
    750 000 x 0,1 x 3 x 365
 +
    <br/><b>~82 millions euros</b><br/>
 +
(~113 millions $)
 +
  </td>
 +
  </tr>
 +
  <tr>
 +
  <td align="center">
 +
    <b>Annual profits</b>
 +
    <br/>(annual income - annual production costs)
 +
  </td>
 +
  <td align="center">
 +
    <b>7,7 millions euros</b><br/>
 +
(~10,5 millions $)
 +
  </td>
 +
  <td align="center">
 +
    <b>57 millions euros</b><br/>
 +
(~78,5 millions $)
 +
  </td>
 +
  </tr>
 +
</tbody>
 +
</table>
 +
 
 +
<h2>Conclusions</h2>
 +
<p>Our treatment will be benetial for both patients, community and pharmaceutical industries !<br/>
 +
Further more, we did not into account other iron overload diseases as thalassemia; the benefitial and the profitability could be even higher !</p>
 +
 
 +
<a id="Ref"></a>
 +
<div id="citation_box">
 +
<p id="references"><b>References:</b></p>
 +
<ol>
 +
<li><a href="http://www.dieti-natura.com/bacteries-lactiques-1104.html?gclid=CPnO9P6WuboCFWfLtAod-ScAsw)"target=‘_blank'>http://www.dieti-natura.com/bacteries-lactiques-1104.html</a></li>
 +
  <li><a href="http://www.cocooncenter.com/Arkopharma-Azinc-Adultes-Probiotiques-30-Comprimes_9129.html?gclid=CIG-pp2ZuboCFe7HtAod3lYA0w)"target=‘_blank'>http://www.cocooncenter.com/Arkopharma-Azinc-Adultes-Probiotiques-30-Comprimes_9129.html</a></li>
-
<h2>Data</h2>
+
  <li><a href="http://www.fleurancenature.fr/complexe-ferments-lactiques.html?origine=L1&mkwid=sMNlWLy44_dc&pcrid=25236698593&kword=probiotiques&match=e&plid=&ectrans=1&gclid=CPukz9WXuboCFWfLtAod-ScAsw&xts=480830&xtor=SEC-2-GOO-[]-[]-S-[probiotiques]&xtdt=23049191)"target=‘_blank'>http://www.fleurancenature.fr/complexe-ferments-lactiques.html</a></li>
-
<p>Cost of the lab' made capsule prototype: 3 cent.</p>
+
</ol>
-
<p>Market price of current probiotic capsules: between 6 and 35 cent.<br/>
+
</div>
-
(http://www.dieti-natura.com/bacteries-lactiques-1104.html?gclid=CPnO9P6WuboCFWfLtAod-ScAsw)<br/>
+
-
(http://www.cocooncenter.com/Arkopharma-Azinc-Adultes-Probiotiques-30-Comprimes_9129.html?gclid=CIG-pp2ZuboCFe7HtAod3lYA0w)<br/>
+
-
(http://www.fleurancenature.fr/complexe-ferments-lactiques.html?origine=L1&mkwid=sMNlWLy44_dc&pcrid=25236698593&kword=probiotiques&match=e&plid=&ectrans=1&gclid=CPukz9WXuboCFWfLtAod-ScAsw&xts=480830&xtor=SEC-2-GOO-[]-[]-S-[probiotiques]&xtdt=23049191)</p>
+
-
<p>The relatively low market price of Iron-Coli capsule is due to the fact that it is easy to produce capsules with only one strand of bacteria. Moreover the patients will have to take 3 capsules each day.</p>
+
-
<p>In France, according to Dr. Françoise Courtois (General Secretary of European Federation of Associations of Patients with Haemochromatosis), bloodletting is charged around 40 euro, but costs in reality around 60 euro. The French public welfare system takes charge of all the costs. If a bacterial treatment enables to save money, it will be a collective benefit.</p>
+
-
<p>According to the presidents of patients' associations, the average number of bloodlettings per patient and per year is 5. Our treatment could theoretically diminish this number by 2.</p>
+
-
<p>According to the presidents of patients' associations, there are around 100 000 patients in France, and 750 000 in Europe.</p>
+

Latest revision as of 01:58, 29 October 2013

Iron coli project

Economy

This section presents an evaluation of the costs for the patient or the community of the treatment, and its possible profitability. All the data used for this evaluation are presented below.

Treatment costs

We first want to know how much will cost our capsule. We estimate that the anticipated market price of 1 capsule of Iron-Coli 10 cent. The relatively low market price of Iron-Coli capsule is due to the fact that it is easy to produce capsules with only one strand of bacteria. Further more the market price of current probiotic capsules is between 6 and 35 cent.1,2,3 Moreover the patients will have to take 3 capsules each day. So our bacterial treatment price per patient and per year will cost: 0.10 x 3 x 365 = 110 euros (~151 $ on the 28/10/2013).


In France, according to Dr. Françoise Courtois (General Secretary of European Federation of Associations of Patients with Haemochromatosis), bloodletting is charged around 40 euros, but costs in reality around 60 euro. The French public welfare system takes charge of all the costs. If a bacterial treatment enables to save money, it will be a collective benefit. According to the presidents of patients' associations, the average number of bloodlettings per patient and per year is 5. The average cost of bloodletting treatment per patient and per year in France is around 300 euros (~413 $).


We established with our flush model that our treatment will decrease by two the iron absorption and thus by two the number of bloodleting for a patient. So the money saved per patient and per year is (300/2)-110=40 euros (~55 $).
This does not take into account the costs of a missing half-day's work, or the costs and time of transport, etc. Thus, the collective benefit could be even higher !


Treatment profitability

We estimated the cost of the lab' made capsule prototype around 3 cents. According to the presidents of patients' associations, there are around 100 000 patients in France, and 750 000 in Europe. Thus we could establish the profitability of our treatment in both France and Europe.

France Europe
Annual production costs 100 000 x 0,03 x 3 x 365
~3,3 millions euros
(~4,5 millions $) 		750 000 x 0,03 x 3 x 365
~25 millions euros
(~34,5 millions $)
Annual income 100 000 x 0,1 x 3 x 365
~11 millions euros
(~15 millions $) 		750 000 x 0,1 x 3 x 365
~82 millions euros
(~113 millions $)
Annual profits
(annual income - annual production costs) 		7,7 millions euros
(~10,5 millions $) 		57 millions euros
(~78,5 millions $)

Conclusions

Our treatment will be benetial for both patients, community and pharmaceutical industries !
Further more, we did not into account other iron overload diseases as thalassemia; the benefitial and the profitability could be even higher !

Retrieved from "http://2013.igem.org/Team:Evry/Economy"